Evaluation framework
How to Choose an MSC Exosome Supplier.
Choosing an MSC exosome supplier is one of the most consequential decisions in exosome research. The quality, consistency, and documentation of your source material directly determines whether your results are reproducible — or unreliable. This guide provides a 5-point framework for evaluating any exosome supplier.
Why supplier selection matters
MSC-derived exosomes are biological materials, not synthetic chemicals. Their properties depend on the cell source, isolation method, storage conditions, and quality control processes used by the supplier. Two suppliers selling "MSC exosomes" can deliver materials with dramatically different particle concentrations, purity profiles, and biological activity.
The proliferation of exosome suppliers — some with rigorous quality systems, others with minimal documentation — makes supplier evaluation critical. Researchers who fail to evaluate suppliers risk publishing non-reproducible results, wasting research budgets, or working with contaminated or misidentified material.
The 5-point evaluation framework
COA quality and independence
What to verify
Is the Certificate of Analysis issued by the supplier itself (in-house) or by an independent third-party laboratory? Third-party verification from a recognized lab like Eurofins provides the highest confidence level because the testing entity has no commercial interest in the results.
Red flags
- COA available only "on request" — not provided upfront
- No testing lab identified on the COA
- Pass/fail results without quantitative data
- COA dated months or years before the lot ship date
Source material documentation
What to verify
What is the MSC source — Wharton's Jelly, bone marrow, adipose tissue, or umbilical cord? The source determines the exosome profile. Donor eligibility documentation (per 21 CFR 1271) should be available for human-derived materials.
Red flags
- Source material not specified
- "Proprietary blend" without source identification
- No donor eligibility documentation
- Source changes between lots without notification
Characterization data completeness
What to verify
Does the supplier provide nanoparticle tracking analysis (NTA) data showing particle size and concentration? Are exosome markers (CD9, CD63, CD81) confirmed by Western blot or flow cytometry? Is endotoxin tested and reported?
Red flags
- No NTA data — particle size and concentration unknown
- No exosome marker confirmation
- Endotoxin not tested or not reported
- "Characterized" claim with no data provided
Lot-to-lot consistency
What to verify
Can the supplier provide multiple lot COAs for comparison? Lot-to-lot consistency in particle concentration, protein content, and marker expression indicates a controlled manufacturing process. Inconsistency suggests process variability that will undermine research reproducibility.
Red flags
- Only one COA available for review
- Lot numbers not traceable to documentation
- No consistency data offered
- Therapeutic or clinical claims for exosome products
- No RUO disclaimer
- Implications of human treatment
- Price without documentation — documentation as upsell
- Third-party COA on every batchEurofins-verified Certificate of Analysis for every exosome lot — not "on request," but standard.
- Wharton's Jelly MSC sourceDocumented source material with donor eligibility records per 21 CFR 1271.
- Lot-linked documentationEvery product identifier, lot number, and quality report is reconcilable.
- Research-use-only complianceNo therapeutic claims. No clinical implications. Clear RUO labeling on all materials.
- USP <71> sterility and USP <85> endotoxin criteriaTesting against recognized pharmacopeial standards.
Regulatory posture and compliance
What to verify
Is the material clearly labeled "For Research Use Only"? Does the supplier make therapeutic or clinical claims about exosome products? No exosome product is FDA-approved for therapeutic use in humans. Suppliers making such claims are misrepresenting their products.
Red flags
Third-party COA vs in-house COA: why it matters
The Certificate of Analysis is the primary quality document for any exosome product. But who issues it matters as much as what it says.
Manufacturer-issued
The same company that sells the product also tests it and writes the COA. This creates an inherent conflict of interest. While many reputable suppliers use in-house testing, the results are inherently less verifiable than third-party testing.
Independent lab verification
An independent laboratory (e.g., Eurofins, Charles River) with no commercial interest in the product performs the testing and issues the COA. This is the gold standard for exosome quality verification. B&H Bio uses Eurofins for third-party COA on every batch.
B&H Bio's approach to supplier quality
B&H Bio was founded on a documentation-first philosophy: evaluate the material, not the marketing. Our quality system includes:
Evaluate for yourself
Request exosome documentation.
Review the actual quality records before you decide. No marketing — just documentation.